GO:0051379 epinephrine binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051379 epinephrine binding is a molecular function defined as the binding of epinephrine (adrenaline) to a receptor or protein, initiating downstream signaling.
• Epinephrine binding to adrenergic receptors activates adenylate cyclase and raises cyclic AMP, a classic hormone-receptor coupling event first demonstrated in erythrocyte membranes.
• Beta1- and beta2-adrenergic receptors in brain, heart, and lung membranes bind epinephrine with high affinity, and this binding is subtype-selective.
• Epinephrine binding sites on liver plasma membranes can be interconverted by trypsin, indicating that receptor conformation and membrane context regulate binding.
• Ferrous iron binding to epinephrine promotes iron oxidation and impedes adrenergic receptor activation, linking metal chemistry to epinephrine binding.
• Leukocytic epinephrine receptors differ between normal and asthmatic individuals, showing that epinephrine binding is relevant to immune and respiratory disease.
Description
Epinephrine binding (GO:0051379) is the molecular function by which the hormone epinephrine, also called adrenaline, interacts with a receptor or binding protein to trigger a cellular response. Epinephrine is produced by the adrenal medulla and increases heart activity, improves muscle power, and increases the rate and depth of breathing, so its binding is a central event in acute stress physiology. At the molecular level, epinephrine binding is best known for activating adrenergic receptors and their associated adenylate cyclase signaling cascade. Early work in erythrocyte membranes showed that epinephrine binding to the catecholamine receptor directly activates adenylate cyclase, establishing the hormone-receptor-cyclic AMP paradigm. Subsequent radioligand studies demonstrated that epinephrine binds beta1- and beta2-noradrenergic receptors in brain, heart, and lung membranes, providing a tissue-level map of this function. Because epinephrine binding controls cardiovascular, pulmonary, metabolic, and immune responses, it is a high-value target for researchers studying receptor pharmacology, signal transduction, and disease mechanisms.
epinephrine binding At A Glance
| GO ID | GO:0051379 |
|---|---|
| GO term | epinephrine binding |
| Ontology | molecular_function |
| Synonym | adrenaline binding |
| Definition | Binding to epinephrine, a hormone produced by the medulla of the adrenal glands that increases heart activity, improves the power and prolongs the action of muscles, and increases the rate and depth of breathing; synthesized by methylation of norepinephrine. |
| Major function | Initiates adrenergic receptor signaling, including adenylate cyclase activation and cyclic AMP production. |
| Representative receptors | Alpha1-adrenoceptor subtypes and beta1/beta2-noradrenergic receptors. |
| Tissue contexts | Erythrocyte membranes, brain, heart, lung, liver plasma membranes, and leukocytes. |
| Chemical modulators | Ferrous iron binding to epinephrine promotes iron oxidation and impedes adrenergic receptor activation. |
What Is GO:0051379?
In the Gene Ontology, GO:0051379 epinephrine binding is defined as binding to epinephrine, a hormone produced by the medulla of the adrenal glands that increases heart activity, improves the power and prolongs the action of muscles, and increases the rate and depth of breathing; epinephrine is synthesized by methylation of norepinephrine. In practical terms, this term describes the selective, non-covalent interaction between epinephrine and a protein such as an adrenergic receptor, which is the first step in epinephrine-dependent signal transduction.
Why Is epinephrine binding Important in Cell Biology?
Epinephrine binding is important because it is the molecular trigger for the body's fight-or-flight response and for numerous therapeutic and pathological processes. The binding event at adrenergic receptors couples hormone recognition to G-protein signaling and cyclic AMP generation, which controls heart rate, airway tone, vascular resistance, and metabolic mobilization. Because epinephrine binding is subtype-selective, it underpins the pharmacology of alpha1- and beta-adrenergic drugs used in cardiovascular and respiratory medicine. Epinephrine binding also intersects with immune function, as leukocytic epinephrine receptors differ between normal and asthmatic individuals, and with metabolic regulation, since beta-adrenergic modulation affects insulin binding in skeletal muscle. Finally, chemical interference with epinephrine binding, such as ferrous iron-promoted oxidation, can impede receptor activation and alter adrenergic signaling.
• Defines the first step in adrenergic receptor activation and cyclic AMP signaling.
• Explains subtype-selective pharmacology of alpha1- and beta-adrenergic receptors.
• Links hormone binding to cardiovascular control in heart and lung membranes.
• Relevant to respiratory disease because leukocytic epinephrine receptors differ in asthma.
• Connects to metabolic regulation through beta-adrenergic modulation of insulin binding in skeletal muscle.
• Shows that membrane context and protease treatment can interconvert epinephrine binding sites in liver plasma membranes.
• Provides a target for understanding how metal ions such as ferrous iron interfere with adrenergic activation.
• Supports drug discovery for adrenergic agonists and antagonists.
• Helps interpret radioligand binding data in brain, heart, and lung tissue.
• Offers a model system for hormone-receptor coupling in erythrocyte membranes.
Molecular Mechanism of epinephrine binding
Hormone recognition and receptor engagement
In simple terms: Epinephrine docks into a specific pocket on a receptor protein, like a key entering a lock.
Epinephrine binding begins when the hormone engages a catecholamine receptor on the cell surface. In erythrocyte membranes, epinephrine binding to the catecholamine receptor was shown to activate adenylate cyclase, defining the receptor as the recognition site for the hormone. Radioligand binding studies with (+/-)-[3H]epinephrine confirmed high-affinity binding to beta1- and beta2-noradrenergic receptors in brain, heart, and lung membranes, demonstrating that epinephrine recognition is subtype-specific and tissue-dependent.
Subtype selectivity at alpha1-adrenoceptors
In simple terms: Different receptor subtypes bind epinephrine with different preferences, which determines the cellular response.
Alpha1-adrenoceptor subtypes are a major class of epinephrine binding proteins. Pharmacological characterization of alpha1-adrenoceptor subtypes established that these receptors mediate distinct responses to catecholamines and are targets of subtype-selective ligands. This subtype diversity explains why epinephrine binding can produce different physiological outcomes in different tissues.
Membrane context and binding site interconversion
In simple terms: The membrane environment and proteases can change how epinephrine binds, switching receptor states.
Epinephrine binding is not static. Treatment of rat liver plasma membranes with trypsin altered the binding of [3H]epinephrine and [3H]-dihydroergocryptine, providing evidence for interconversion of binding sites. This indicates that membrane protein context and proteolytic processing can modulate the epinephrine binding function.
Chemical interference by ferrous iron
In simple terms: Iron can react with epinephrine and block its ability to activate receptors.
Ferrous iron binding to epinephrine promotes the oxidation of iron and impedes activation of adrenergic receptors. This chemical modification of the ligand shows that epinephrine binding can be disrupted by metal-catalyzed oxidation, adding a non-receptor layer of regulation to GO:0051379.
Downstream coupling to adenylate cyclase
In simple terms: Once epinephrine is bound, the receptor turns on an enzyme that makes cyclic AMP, a cellular alarm signal.
The functional consequence of epinephrine binding is activation of adenylate cyclase and production of cyclic AMP, as demonstrated in erythrocyte membranes. This coupling converts the binding event into a biochemical signal that changes cell behavior, and it is the mechanistic basis for classifying GO:0051379 as a signaling-related molecular function.
Key Genes Involved in GO:0051379 epinephrine binding
The following genes and proteins are directly implicated in epinephrine binding or in the receptor systems that mediate it, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRA1A | Alpha1-adrenoceptor subtype that binds catecholamines including epinephrine | Subtype-selective pharmacology and cardiovascular research |
| ADRA1B | Alpha1-adrenoceptor subtype mediating epinephrine responses | Receptor subtype characterization |
| ADRA1D | Alpha1-adrenoceptor subtype with distinct binding profile | Subtype-specific drug targeting |
| ADRB1 | Beta1-noradrenergic receptor that binds epinephrine in brain and heart | Cardiac and neuronal signaling studies |
| ADRB2 | Beta2-noradrenergic receptor that binds epinephrine in lung and brain | Pulmonary and metabolic research |
| ADRB3 | Beta3-adrenergic receptor family member | Metabolic and adipose signaling context |
| ADRA2A | Alpha2-adrenoceptor family member | Presynaptic catecholamine regulation |
| ADRA2B | Alpha2-adrenoceptor family member | Catecholamine feedback control |
| ADRA2C | Alpha2-adrenoceptor family member | Adrenergic signaling diversity |
| GNAS | G protein alpha subunit coupling receptors to adenylate cyclase | Cyclic AMP signaling downstream of epinephrine binding |
| ADCY1 | Adenylate cyclase isoform producing cyclic AMP | Effector enzyme in epinephrine signaling |
| ADCY2 | Adenylate cyclase isoform | Cyclic AMP generation in neural tissue |
| SLC6A2 | Norepinephrine transporter affecting catecholamine availability | Indirect modulation of epinephrine binding |
| COMT | Catechol-O-methyltransferase degrading catecholamines | Controls epinephrine levels and binding availability |
| MAOA | Monoamine oxidase A degrading catecholamines | Regulates epinephrine turnover |
| MAOB | Monoamine oxidase B degrading catecholamines | Catecholamine metabolism context |
| INSR | Insulin receptor modulated by beta-adrenergic signaling | Cross-talk between epinephrine binding and insulin action |
How Is epinephrine binding Regulated?
Epinephrine binding is regulated at multiple levels. Receptor subtype expression determines which cells respond, as shown by the distinct binding profiles of beta1- and beta2-noradrenergic receptors in brain, heart, and lung membranes. Membrane protein context and proteolytic processing can interconvert epinephrine binding sites in liver plasma membranes, indicating local regulation of binding site conformation. Ligand availability is controlled by catecholamine synthesis and degradation, and chemical modification of epinephrine by ferrous iron can impede receptor activation. In addition, beta-adrenergic signaling modulates insulin binding in skeletal muscle, showing that epinephrine binding is integrated with metabolic regulatory networks.
epinephrine binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADRB2 | Asthma and airway hyperresponsiveness | Knockout and point-mutation airway epithelial cell models |
| ADRB1 | Cardiovascular dysfunction | Cardiomyocyte knockout and knock-in models |
| ADRA1A | Hypertension and vascular tone | Vascular smooth muscle knockout models |
| INSR | Insulin resistance and metabolic disease | Skeletal muscle overexpression and knockout models |
| COMT | Catecholamine-related stress disorders | Neuronal knockout and point-mutation models |
Asthma and allergic airway disease
Leukocytic epinephrine receptors of asthmatic individuals differ from those of normal individuals, suggesting that altered epinephrine binding on immune cells contributes to asthma biology. This makes epinephrine binding a relevant function for studying airway inflammation and beta-agonist responsiveness.
Cardiovascular disease
Beta1-noradrenergic receptors in heart membranes bind epinephrine and mediate cardiac responses, so changes in epinephrine binding can influence heart rate and contractility. Alpha1-adrenoceptor subtypes are also drug targets in cardiovascular pharmacology.
Metabolic and insulin resistance disorders
Beta-adrenergic modulation of insulin binding in skeletal muscle links epinephrine binding to glucose metabolism and insulin sensitivity. This connection is relevant to metabolic disease research.
Oxidative stress and metal-related dysfunction
Ferrous iron binding to epinephrine promotes iron oxidation and impedes adrenergic receptor activation, linking epinephrine binding to oxidative stress and metal homeostasis. This mechanism may be relevant in conditions with iron dysregulation.
From epinephrine binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ADRB2 alter epinephrine binding and cyclic AMP signaling? | ADRB2 knockout cell line |
| Does a point mutation in the epinephrine binding pocket change receptor affinity? | Point-mutation knock-in of ADRB2 |
| Can a tagged receptor be used to track epinephrine binding in live cells? | Tagged knock-in of ADRB1 or ADRB2 |
| Does overexpression of ADRA1A increase epinephrine-dependent calcium signaling? | ADRA1A overexpression cell model |
| Does ferrous iron exposure reduce epinephrine binding to adrenergic receptors? | Wild-type and mutant receptor cells treated with iron |
| Does beta-adrenergic signaling modulate insulin binding in muscle cells? | INSR overexpression and ADRB knockout muscle models |
How to Study the epinephrine binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Affinity and density of epinephrine binding sites | Receptor characterization in membranes |
| Cyclic AMP assay | Downstream signaling after epinephrine binding | Functional coupling to adenylate cyclase |
| Subtype-selective pharmacology | Receptor subtype specificity | Alpha1 and beta receptor classification |
| Trypsin treatment assay | Interconversion of binding sites | Membrane protein regulation studies |
| Iron oxidation assay | Chemical modification of epinephrine | Metal-ligand interference studies |
| Leukocyte binding assay | Immune cell epinephrine receptor function | Asthma and allergy research |
| Insulin binding assay | Beta-adrenergic modulation of insulin receptor | Skeletal muscle metabolic studies |
| Aprotinin-related coagulation assays | Thrombotic risk context | Pharmacological safety studies |
Radioligand binding assays
Radioligand binding with [3H]epinephrine and related ligands is the classic method for measuring epinephrine binding affinity and receptor density in membranes from brain, heart, and lung. This approach also revealed interconversion of binding sites in liver plasma membranes after trypsin treatment.
Cyclic AMP and adenylate cyclase assays
Because epinephrine binding activates adenylate cyclase, measuring cyclic AMP production provides a functional readout of the binding event. Erythrocyte membrane preparations were used historically to demonstrate this coupling.
Pharmacological subtype profiling
Subtype-selective agonists and antagonists can distinguish alpha1-adrenoceptor subtypes and beta1/beta2 receptors, allowing researchers to assign epinephrine binding to specific gene products.
Cell-based immune and metabolic assays
Leukocyte preparations from normal and asthmatic donors can be used to compare epinephrine receptor binding and function, while skeletal muscle models can assess beta-adrenergic modulation of insulin binding.
How CRISPR Can Be Used to Study GO:0051379 epinephrine binding
Knockout
CRISPR knockout of ADRB1, ADRB2, or ADRA1A can remove epinephrine binding sites and reveal which receptor subtype mediates a given response. Knockout models are useful for separating binding events from downstream cyclic AMP signaling.
Point Mutation
Point mutations in the ligand-binding pocket of adrenergic receptors can test which residues are required for epinephrine binding and subtype selectivity. Such models help validate radioligand binding data at the structural level.
Knock-in
Knock-in of tagged or fluorescent receptors allows real-time tracking of epinephrine binding and receptor trafficking in live cells. Knock-in of human receptor variants can also model disease-associated differences in binding.
Overexpression
Overexpression of ADRA1A, ADRB1, or ADRB2 increases the number of epinephrine binding sites and amplifies downstream signaling, which is useful for biochemical assays and drug screening. Overexpression of INSR in muscle models can test cross-talk with beta-adrenergic signaling.
How EDITGENE Supports epinephrine binding Research
Researchers studying epinephrine binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, signaling, or disease. EDITGENE provides CRISPR-based cell models that make it possible to test these questions directly in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for epinephrine binding research.
Frequently Asked Questions About epinephrine binding
What is epinephrine binding?
Epinephrine binding (GO:0051379) is the molecular function of binding to epinephrine, a hormone that increases heart activity, muscle power, and breathing rate, and is synthesized by methylation of norepinephrine.
What genes are involved in epinephrine binding?
Genes encoding adrenergic receptors such as ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2, and ADRB3 are directly involved in epinephrine binding.
What is the GO ID for epinephrine binding?
The Gene Ontology ID for epinephrine binding is GO:0051379, with the synonym adrenaline binding.
How does epinephrine binding activate cells?
Epinephrine binding to catecholamine receptors activates adenylate cyclase and increases cyclic AMP, as shown in erythrocyte membranes.
Which receptors bind epinephrine in the heart and lung?
Beta1- and beta2-noradrenergic receptors bind epinephrine in brain, heart, and lung membranes.
Can epinephrine binding be altered by proteases?
Yes, trypsin treatment of rat liver plasma membranes interconverts epinephrine binding sites, showing that binding can be modulated.
Does iron affect epinephrine binding?
Ferrous iron binding to epinephrine promotes iron oxidation and impedes activation of adrenergic receptors.
Is epinephrine binding different in asthma?
Leukocytic epinephrine receptors differ between normal and asthmatic individuals, suggesting disease-related changes in binding.
How is epinephrine binding measured in the lab?
Radioligand binding assays with [3H]epinephrine and cyclic AMP assays are standard methods for measuring epinephrine binding and its downstream effects.
What CRISPR models are used to study epinephrine binding?
Knockout, point-mutation, knock-in, and overexpression models of adrenergic receptor genes are used to dissect epinephrine binding and signaling.
Conclusion
Epinephrine binding (GO:0051379) is a well-defined molecular function that captures the first step in adrenergic hormone signaling. From the classic demonstration of receptor-adenylate cyclase coupling in erythrocyte membranes to subtype-selective binding in brain, heart, and lung, the literature shows that epinephrine binding is tissue-specific, pharmacologically diverse, and sensitive to membrane context and chemical modification. Its relevance extends to asthma, cardiovascular biology, and metabolic regulation. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide a direct way to test how specific genes control epinephrine binding and its downstream effects.
References
- 1. Jačić JK et al.. 2020. Ferrous iron binding to epinephrine promotes the oxidation of iron and impedes activation of adrenergic receptors.. Free Radic Biol Med 148:123-127 PMID: 31911148
- 2. Zhong H et al.. 1999. Alpha1-adrenoceptor subtypes.. Eur J Pharmacol 375(1-3):261-76 PMID: 10443582
- 3. Schramm M et al.. 1972. Epinephrine binding to the catecholamine receptor and activation of the adenylate cyclase in erythrocyte membranes (hormone receptor- -adrenergic receptor-cyclic AMP-turkey).. Proc Natl Acad Sci U S A 69(2):523-7 PMID: 4501130
- 4. U'Prichard DC et al.. 1978. (+/-)-[3H]Epinephrine and (-)[3H]dihydroalprenolol binding to beta1- and beta2-noradrenergic receptors in brain, heart, and lung membranes.. J Biol Chem 253(14):5090-102 PMID: 209026
- 5. El-Refai MF et al.. 1980. Effects of trypsin on binding of [3H]epinephrine and [3H]-dihydroergocryptine to rat liver plasma membranes. Evidence for interconversion of binding sites.. J Biol Chem 255(12):5853-8 PMID: 6247349
- 6. Poullis M et al.. 2001. Aprotinin: is it prothrombotic?. Perfusion 16(5):401-9 PMID: 11565895
- 7. Webster B et al.. 1986. Beta-adrenergic modulation of insulin binding in skeletal muscle.. Am J Physiol 250(2 Pt 1):E198-204 PMID: 3513608
- 8. Sokol WN et al.. 1975. Leukocytic epinephrine receptors of normal and asthmatic individuals.. J Allergy Clin Immunol 55(5):310-24 PMID: 164491
